SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-24-000124
Filing Date
2024-07-08
Accepted
2024-07-08 07:14:32
Documents
17
Period of Report
2024-07-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K xers-20240707.htm   iXBRL 8-K 38071
2 EX-10.1 transitionagreementdatedas.htm EX-10.1 74528
3 EX-10.2 secondamendedandrestatedem.htm EX-10.2 97031
4 EX-99.1 exh991pressreleasedatedjul.htm EX-99.1 14894
8 picture1reviseda.jpg GRAPHIC 4446
  Complete submission text file 0001867096-24-000124.txt   402328

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20240707.xsd EX-101.SCH 1901
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20240707_lab.xml EX-101.LAB 22548
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20240707_pre.xml EX-101.PRE 13046
19 EXTRACTED XBRL INSTANCE DOCUMENT xers-20240707_htm.xml XML 2833
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 241103346
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)